Drug General Information (ID: DDI8A62VKM)
Drug Name			Alemtuzumab		Drug Info		Diflunisal		Drug Info
Drug Type		Monoclonal antibody				Small molecule
Therapeutic Class		Antineoplastics				Analgesics

Mechanism of Alemtuzumab-Diflunisal Interaction (Severity Level: Moderate)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Alemtuzumab				Diflunisal
Mechanism		Risk of bleeding Antiplatelet/anticoagulant effects				Risk of bleeding Antiplatelet effects
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Alemtuzumab and Diflunisal

Recommended Action
Management		Caution is recommended if alemtuzumab is used concomitantly with NSAIDS. Patients should be monitored for increased anticoagulant effects and bleeding complications. Patients should be advised to promptly report any signs of unusual bleeding or bruising to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, red or brown urine, or red or black stools.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Cerner Multum, Inc. "Canadian Product Information.".
3	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
4	Product Information. Campath (alemtuzumab) Berlex, Richmond, CA.